Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Recommendation of “Buy” from Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have received a consensus rating of “Buy” from the fifteen research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $100.25.

A number of equities analysts have recently commented on MIRM shares. JPMorgan Chase & Co. raised their price objective on shares of Mirum Pharmaceuticals from $53.00 to $77.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. Wall Street Zen raised shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, September 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 price target on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Morgan Stanley lifted their price objective on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the company an “overweight” rating in a research note on Tuesday, December 9th. Finally, TD Cowen upgraded Mirum Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, September 25th.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $81.12 on Thursday. Mirum Pharmaceuticals has a 12 month low of $36.88 and a 12 month high of $82.58. The firm’s 50 day moving average is $70.90 and its 200 day moving average is $65.33. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. The stock has a market capitalization of $4.17 billion, a P/E ratio of -94.32 and a beta of 0.42.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. The company had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm’s revenue for the quarter was up 47.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.30) EPS. On average, sell-side analysts anticipate that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Jump Financial LLC lifted its holdings in shares of Mirum Pharmaceuticals by 839.7% in the 2nd quarter. Jump Financial LLC now owns 148,689 shares of the company’s stock worth $7,567,000 after acquiring an additional 132,866 shares during the last quarter. Contravisory Investment Management Inc. bought a new position in shares of Mirum Pharmaceuticals during the 2nd quarter valued at $270,000. Woodline Partners LP raised its position in Mirum Pharmaceuticals by 40.0% in the 1st quarter. Woodline Partners LP now owns 566,271 shares of the company’s stock worth $25,511,000 after purchasing an additional 161,867 shares during the period. Emerald Mutual Fund Advisers Trust bought a new stake in Mirum Pharmaceuticals in the second quarter worth $11,071,000. Finally, Eventide Asset Management LLC boosted its position in Mirum Pharmaceuticals by 4.4% during the second quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock valued at $134,224,000 after buying an additional 110,485 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.